Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Insmed Inc INSM

Healthcare Biotechnology
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs... see more

Recent & Breaking News (NDAQ:INSM)

ARIKACE to Receive Orphan Medicinal Product Designation in the European Union to Treat Lung Infections Caused by Nontuberculous Mycobacteria

eTeligis February 10, 2014

Insmed to Present at the Leerink Swann Global Healthcare Conference

eTeligis February 4, 2014

RDInvesting Provides Investors with Free In-Depth Equity Reports on AGU, CCJ, INSM and MDLZ

Accesswire January 10, 2014

Insmed Reports Third Quarter 2013 Financial Results

Marketwired November 5, 2013

Insmed Appoints David W.J. McGirr to Its Board of Directors

Marketwired November 1, 2013

Insmed to Host Third Quarter 2013 Financial Results Conference Call on Tuesday, November 5, 2013

Marketwired October 23, 2013

Insmed Completes Enrollment of Phase 2 Clinical Trial of ARIKACE to Treat Nontuberculous Mycobacteria Lung Disease in U.S. and Canada

Marketwired October 15, 2013

Insmed to Present at Leerink Swann Rare Disease Roundtable

Marketwired September 25, 2013

Insmed Fortifies Global Patent Portfolio

Marketwired September 11, 2013

Insmed to Participate in the Stifel Healthcare Conference 2013

Marketwired September 4, 2013

Insmed to Participate in August Investor Conferences

Marketwired August 7, 2013

Insmed Reports Second Quarter Financial Results

Marketwired August 6, 2013

Insmed to Host Second Quarter 2013 Financial Results Conference Call on Tuesday, August 6, 2013

Marketwired July 31, 2013

Insmed Appoints Christine Pellizzari as General Counsel and Corporate Secretary

Marketwired July 29, 2013

Insmed Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares

Marketwired July 22, 2013

Insmed Announces Pricing of Public Offering of Common Stock

Marketwired July 17, 2013

Insmed Announces Proposed Public Offering of Common Stock

Marketwired July 15, 2013

Insmed to Present at the 8th Annual JMP Securities Healthcare Conference

Marketwired July 8, 2013

Acquisitions, Corporate Restructurings, and Pipeline Developments Open Opportunities for Growth - Research Report on Boston Scientific, Covidien, Hospira, Insmed, and Thoratec

PR Newswire July 4, 2013

Five Star Equities Issues New Research Reports on ACUR, ELGX, INSM and NWSA

Accesswire July 2, 2013
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested